PT - JOURNAL ARTICLE AU - Rachida Lebtahi AU - Joseph Le Cloirec AU - Claire Houzard AU - Doumit Daou AU - Iradj Sobhani AU - Geneviève Sassolas AU - Michel Mignon AU - Patrick Bourguet AU - Dominique Le Guludec TI - Detection of Neuroendocrine Tumors: <sup>99m</sup>Tc-P829 Scintigraphy Compared with <sup>111</sup>In-Pentetreotide Scintigraphy DP - 2002 Jul 01 TA - Journal of Nuclear Medicine PG - 889--895 VI - 43 IP - 7 4099 - http://jnm.snmjournals.org/content/43/7/889.short 4100 - http://jnm.snmjournals.org/content/43/7/889.full SO - J Nucl Med2002 Jul 01; 43 AB - The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, 99mTc-P829, compared with that of 111In-pentetreotide. Methods: Forty-three patients (32 men, 11 women; age range, 24–78 y; mean age, 56 y) with biologically or histologically proven neuroendocrine tumors were prospectively included: 11 patients with Zollinger-Ellison syndrome, 16 patients with carcinoid tumors, and 16 patients with other types of functioning (n = 6) or nonfunctioning (n = 10) endocrine tumors. 111In-Pentetreotide planar images (head, chest, abdomen, and pelvis) were obtained 4 and 24 h after injection of 10 μg somatostatin analog labeled with 148 ± 17 MBq 111In, and SPECT was performed 24 h after injection. Similar 99mTc-P829 planar images were obtained at 1, 4–6, and 24 h after injection of 50 μg peptide labeled with 991.6 ± 187.59 MBq 99mTc. Abdominal SPECT was performed 4–6 h after injection. Results: 111In-Pentetreotide detected 203 tumoral sites in 39 (91%) of 43 patients, whereas 99mTc-P829 detected 77 sites in 28 (65%) of 43 patients (P &lt; 0.005). In the liver, 129 sites (in 24 patients) were detected by 111In-pentetreotide scintigraphy and 34 sites (in 10 patients) were detected by 99mTc-P829 scintigraphy. Conclusion: In patients with endocrine tumors, the detection rate of 99mTc-P829 scintigraphy was lower than that of 111In-pentetreotide scintigraphy, which appeared to be more sensitive, especially for liver metastases.